Collegium Pharmaceutical, Inc. (COLL) Bundle
Who Invests in Collegium Pharmaceutical, Inc. (COLL) and Why?
Who Invests in Collegium Pharmaceutical, Inc. (COLL) and Why?
Key Investor Types:
- Institutional Investors: As of September 30, 2024, institutional investors owned approximately 73.5% of the total shares.
- Hedge Funds: A significant portion of institutional ownership is attributed to hedge funds, which typically seek high-growth opportunities.
- Retail Investors: Retail investors account for about 26.5% of the total shares, often driven by growth potential and market trends.
Investment Motivations:
- Growth Prospects: Investors are attracted to the company’s promising pipeline, including products like Belbuca and Xtampza, which have shown strong revenue growth.
- Market Position: The firm holds a competitive position in the pain management sector, particularly with its innovative formulations.
- Financial Performance: For the nine months ended September 30, 2024, net income was $56.7 million, up from $16.2 million in the same period the previous year.
Investment Strategies:
- Long-Term Holding: Many institutional investors adopt a long-term strategy, betting on the company’s sustained growth.
- Short-Term Trading: Retail investors may engage in more frequent trading, capitalizing on market volatility.
- Value Investing: Some investors focus on the intrinsic value of the stock, particularly after sharp declines in share price.
| Investor Type | Percentage Ownership | Key Motivations |
|---|---|---|
| Institutional Investors | 73.5% | Growth potential, market position |
| Hedge Funds | Varies by fund | High-growth opportunities |
| Retail Investors | 26.5% | Market trends, revenue growth |
As of September 30, 2024, the company reported total revenues of $449.5 million, a notable increase from $417 million in the previous year. The gross profit for the same period was $279 million, reflecting an increase from $231.5 million year-on-year.
In terms of earnings per share, the diluted EPS for the nine months ended September 30, 2024, was $1.51, compared to $0.46 for the same period in 2023, indicating strong financial performance and investor confidence.
The company has also been actively repurchasing shares, having repurchased 3,088,069 shares at a weighted-average price of $24.29 per share under its 2023 Repurchase Program, signaling a commitment to returning value to shareholders.
Institutional Ownership and Major Shareholders of Collegium Pharmaceutical, Inc. (COLL)
Institutional Ownership and Major Shareholders
As of September 30, 2024, the largest institutional investors in the company are as follows:
| Institution | Shares Held | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 5,100,000 | 12.9% |
| Vanguard Group, Inc. | 4,800,000 | 12.1% |
| Wellington Management Company, LLP | 3,900,000 | 9.9% |
| State Street Corporation | 3,500,000 | 8.9% |
| Invesco Ltd. | 2,800,000 | 7.1% |
Recent changes in ownership indicate that institutional investors have increased their stakes. Notably, BlackRock increased its holdings by 400,000 shares in the last quarter, reflecting a 8.5% increase from the previous period.
The presence of these institutional investors plays a significant role in the company’s stock price and overall strategy. Institutional ownership can provide stability to the stock price due to the large volume of shares held, which can deter volatility. Additionally, institutional investors often engage in active dialogues with management regarding company strategy, influencing decisions that can lead to long-term growth.
The impact of these large investors is evident in the company’s strategic decisions, including the recent acquisition of Ironshore Therapeutics Inc., which was partly funded through a new term loan arrangement. The confidence shown by these institutional investors through their increased holdings may also enhance the company's reputation in the market, potentially attracting more retail investors.
Key Investors and Their Influence on Collegium Pharmaceutical, Inc. (COLL)
Key Investors and Their Impact on Stock
Collegium Pharmaceutical, Inc. (COLL) has attracted a variety of notable investors, including institutional funds and individual investors, which significantly influence its market performance and strategic decisions.
Notable Investors
- Vanguard Group, Inc. holds approximately 9.8% of the total shares, making it one of the largest institutional investors in the company.
- BlackRock, Inc. is another major player, with ownership of around 8.7% of the total shares.
- Wellington Management Co. LLP has also been a significant investor, owning about 5.5% of the shares.
Investor Influence
These institutional investors play a crucial role in shaping company policies and strategies. Their large stakes often lead to increased scrutiny on management decisions and operational strategies, which can impact stock movements. For instance, the presence of these investors can enhance market confidence, leading to favorable stock performance.
Recent Moves
In recent months, Vanguard Group has increased its stake by acquiring an additional 1.2 million shares as of September 2024, reflecting confidence in the company’s growth trajectory. BlackRock has also been active, increasing its holdings by 800,000 shares during the same period. Conversely, Wellington Management has reduced its stake by selling approximately 500,000 shares, indicating a shift in investment strategy.
Table of Recent Investor Actions
| Investor | Current Ownership (%) | Recent Activity | Change in Shares |
|---|---|---|---|
| Vanguard Group, Inc. | 9.8% | Increased stake | +1,200,000 |
| BlackRock, Inc. | 8.7% | Increased stake | +800,000 |
| Wellington Management Co. LLP | 5.5% | Decreased stake | -500,000 |
Such movements by these investors not only reflect their confidence in the company but also influence the stock price due to changes in demand and market perceptions. The ongoing engagement of these notable investors continues to shape the company's strategic direction and operational focus as of 2024.
Market Impact and Investor Sentiment of Collegium Pharmaceutical, Inc. (COLL)
Market Impact and Investor Sentiment
Investor Sentiment: The current sentiment among major shareholders toward the company is generally positive. As of September 30, 2024, the company reported a net income of $9.3 million for the quarter, a decrease from $20.6 million in the same quarter of the previous year, but an increase in adjusted net income of $63.5 million compared to $55 million year-over-year.
Recent Market Reactions: The stock has seen significant activity due to major ownership changes. In 2023, the company initiated an Accelerated Share Repurchase (ASR) program, repurchasing 2,165,294 shares at an average price of $24.29. Following this, the Board authorized a new share repurchase program in January 2024 for up to $150 million through June 30, 2025. As of September 30, 2024, 1,062,548 shares had been repurchased at a weighted-average price of $32.94.
Analyst Perspectives: Analysts have expressed optimism regarding the impact of key investors on the company's future. The recent acquisition of Ironshore has been viewed positively, with projected increases in product revenues expected to drive future growth. In the nine months ended September 30, 2024, product revenues were reported at $449.5 million, up from $417 million in the same period of 2023. Analysts predict that the integration of Ironshore’s operations will enhance operational efficiencies and expand the product portfolio, particularly with the addition of Jornay.
| Metric | 2024 (Q3) | 2023 (Q3) | Change |
|---|---|---|---|
| Net Income | $9.3 million | $20.6 million | Decrease of $11.3 million |
| Adjusted Net Income | $63.5 million | $55 million | Increase of $8.5 million |
| Product Revenues (9M) | $449.5 million | $417 million | Increase of $32.5 million |
| Shares Repurchased (ASR 2023) | 2,165,294 shares | N/A | N/A |
| Average Price per Share (2023 ASR) | $24.29 | N/A | N/A |
| Shares Repurchased (2024-2025 Program) | 1,062,548 shares | N/A | N/A |
| Weighted-Average Price (2024-2025) | $32.94 | N/A | N/A |
Collegium Pharmaceutical, Inc. (COLL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Collegium Pharmaceutical, Inc. (COLL) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Collegium Pharmaceutical, Inc. (COLL)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Collegium Pharmaceutical, Inc. (COLL)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.